Infliximab in Russian clinical practice
The study of infliximab began (INF) in Russia in 2001. It was the first genetically engineered biological agent (GEBA) registered in our country to treat patients with rheumatoid arthritis (RA). With the advent of infliximab, a Russian biological rheumatoid arthritis therapy registry started its wor...
Main Authors: | G V Lukina, Ya A Sigidin, E S Pozdnyakova, E N Aleksandrova, A A Novikov, A V Smirnov, S I Glukhova, E L Nasonov |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA-PRESS LLC
2012-09-01
|
Series: | Современная ревматология |
Subjects: | |
Online Access: | https://mrj.ima-press.net/mrj/article/view/429 |
Similar Items
-
Clinical experience with infliximab administration in patients with rheumatoid arthritis by Russian register data
by: Galina Viktorovna Lukina, et al.
Published: (2009-08-01) -
Infliximab in the therapy of rheumatoid arthritis
by: G. V. Lukina, et al.
Published: (2016-05-01) -
Infliximab tolerance in patients with rheumatoid arthritis in real clinical practice
by: E. S. Aronova, et al.
Published: (2020-02-01) -
EFFICACY OF INFLIXIMAB IN RHEUMATOID ARTHRITIS: A RELATIONSHIP TO THE TOTAL DOSE OF THE DRUG
by: E. S. Aronova, et al.
Published: (2015-10-01) -
INFLIXIMAB: HAVE ALL QUESTIONS BEEN ANSWERED FOR 10 YEARS?
by: R M Balabanova, et al.
Published: (2010-03-01)